-- Humanwell Healthcare (SHA:600079) unit obtained China's regulatory approval to begin clinical trials for RFUS-188 to treat acute pain, according to a Thursday filing with the Shanghai bourse.
The drug targets peripheral kappa opioid receptors without crossing the blood-brain barrier, potentially eliminating the addiction, respiratory depression and other severe side effects of traditional opioids
Shares of the pharmaceutical company declined 1% in recent trade.